Research Article
An ANOCEF Genomic and Transcriptomic Microarray Study of the Response to Irinotecan and Bevacizumab in Recurrent Glioblastomas
Table 1
Patient characteristics.
| | | Nonresponders | Responders | |
| | Number of patients | 13 | 12 | | | Median age (years) at diagnosis (range) | 56 (37–69) | 62 (57–72) | t-test P = 0.01 | | Biopsy/resection (%) | 0/100 | 25/75 | | | Initial treatment (%) | RTCT (100%) | RTCT (100%) | | | Median delay (months) between diagnosis and bev./iri. onset (range) | 11 (7–22) | 13 (5–27) | Ns | | Recurrence number at bev./iri. onset | | | | | First | 8 | 7 | | | Second | 4 | 5 | | | Third | 1 | 0 | | | Median KPS at bev./iri. onset | 70 | 80 | Ns | | Median PFS after bev./iri. onset (months) | 2.4 | 9.4 | P < 0.0001 | | Median OS after bev./iri. onset (months) | 6.4 | 18.9 | P = 0.0001 | | Median OS since diagnosis (months) | 18.3 | 36.4 | P = 0.002 |
|
|
RTCT: temozolomide radiochemotherapy; bev./iri.: bevacizumab/irinotecan chemotherapy; KPS: Karnofsky performance status; PFS: progression-free survival; OS: overall survival; ns: not significant.
|
